HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech's structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated startups will operate thorough scientific research and EFS (equity for support ) model.

HBM has made significant progress since its establishment in late-2016, through strategic collaborations and partnerships with major academic institutions and biotech and pharmaceutical companies across the world. The business has successfully built a robust portfolio of early and late stage assets in immune-oncology and immunology, through organic R&amp;D as well as in-licensing tactical assets that tackle high unmet medical needs throughout the world. Its internally discovered next generation ani-CTLA-4 antibody HBM4003 for solid tumors, based on its HCAb stage is already in phase 1 clinical trials.
<blockquote>"We are excited to combine our capabilities with those of Viva Biotech's to offer innovative startup companies' access to our next generation technology platforms and unique R&amp;D capabilities. We are always on the lookout for innovation that can positively impact human life, and this partnership will allow us to enable the translation of such ideas to products that have global impact. Some of these innovative startups may become the next big biotech in the industry. We look forward to supporting them in multiple ways, including mentoring, alongside HBM's and Viva Biotech's management teams."-Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed</blockquote>
Viva Biotech provides world-leading structure-based drug discovery solutions to its own biotechnology and pharmaceutical clients worldwide for their pre-clinical phase innovative drug development.
<blockquote>"The strategic partnership between Viva Biotech and Harbour BioMed makes up for Viva Biotech's deficiency in transgenic mouse platforms for generating fully human monoclonal antibodies, and will further enhance the scalability of Viva Biotech's business model, thereby strengthening its ability in attracting and incubating more innovative startups."-Dr. Delin Ren, the president of Viva Biotech</blockquote>
The Group covers the full spectrum of the clients' requirements for early stage drug discovery, such as biological target protein expression and structure study, drug screening, lead optimization, and clinical candidate choice. The Group also provides discovery and incubation services to biotechnology start-ups with higher potential beneath its EFS (fairness for support ) model.
<div class="content-src-label"><strong>Source:</strong></div>
<div class="content-src-value">

<span style="color: #ff6600;"><a style="color: #ff6600;" href="http://www.harbourbiomed.com/en/newsContent.html#181" target="_blank" rel="nofollow noopener noreferrer">Harbour BioMed</a></span>

</div>